Management Team


Dr Baker was an Investment Manager with the leading Australian life science fund, BioScience Managers, where he was responsible for deal sourcing from networks, conferences, universities and research institutes. He also conducted due diligence to shortlist investment opportunities and played an active role in managing portfolio companies. Michael was a senior manager at Hexima Limited which specialises in developing agricultural and pharmaceutical products.

Dr Baker has a PhD in Biochemistry and was also awarded the prestigious Nancy Millis award for the most outstanding thesis for the Faculty of Science, Technology and Engineering, 2010. He was an Alexander von Humboldt Research Fellow at the University of Cologne with nine publications, one in the prestigious journal Science. He was also awarded an MBA at Melbourne Business School, where he was included in the Dean’s Honours List for being in the top 10% of graduating students.




Tony has over 25 years’ experience in the healthcare industry working for multinational companies and Australian start-ups, within technical, commercial, and executive roles. Tony has spent the past 12 years in the biotech industry responsible for designing and running GMP compliant operations with continuous improvement, cost savings and commercial success as his main areas of focus.

Tony has a Bachelor Science in Medical Science, Graduate Certificate of Management and holds Fellowships at both the Australian Institute of Management and Institute of Manager and Leaders.



Dr. Buchanan has 20 years’ of experience in the cell and gene therapy industry, focused on process development, technology transfer, manufacturing, and quality. Sandhya is dedicated to bringing innovative medicines to patients through pioneering science, teamwork, and a commitment to excellence.

Dr Buchanan joined SUDA from Atara Biotherapeutics, a biotechnology company pioneering off-the-shelf cell therapies for treating cancer and autoimmune disease.

Prior to Atara, Dr Buchanan held several senior roles at Atara Biotherapeutics, FujiFilm Diosynth, and Novartis, where she was responsible for leading Product and Process Development, as well as supporting Manufacturing and Quality Operations.

Dr Buchanan received her bachelor’s degree in chemistry with high distinction and biological honors and doctorate in Pharmaceutical Sciences from the University of Colorado.



Dr Deborah Cooper is a Biotech professional with 25 years’ experience, expert in Cell Biology/Immunology, Clinical, Manufacturing, Product Development and Project Management. Deborah has 12 years in management of commercial technology organisations, including 7 years at the executive level. Deborah has worked for 4 years as an independent consultant to the Biotech sector, involved in managing product development, commercialisation strategy, regulatory submissions, grant applications, feasibility studies, GMP facilities, intellectual property management and placement of contract manufacturing, pre-clinical and clinical studies. Deborah has worked for 9 years in scientific research in private, not for profit and academic organisations; and 7 years studying at recognised tertiary institutions, achieving qualifications to the PhD level in the biological sciences arena.



Uthayamalar Armugam is a Project Management Professional (PMP) certified; lean sigma green belt accredited with over 20 years of operational pharmaceutical experience in multiple disciplines. Malar is an accomplished individual in Quality, Operational Excellence, Supply Chain, Program Management Office (PMO) and Portfolio & Project Management. Expertise in Project Management, Good Manufacturing Practice (GMP), Good Clinical Practice (GCP) and Lean Sigma principles.

Malar has worked in multinational companies and local companies such as GSK, Sigma, Pfizer and Mayne prior to joining us. She holds B. Sc (Hons) in Chemistry from the prestigious University of Malaya, Malaysia. Currently pursuing Master’s in Business Administration (MBA) at RMIT Melbourne, aiming for completion in October 2021.